Seven threads — the deliberate shrink, the margin improvement, the new CEO, and the raised guidance.
↓ scroll to read
✦ The bottom line
agilon's Q1 release is a turnaround update. Here's how management framed the quarter.
↓ the brief below
✦ Seven threads from the Q1 2026 earnings release
1
Revenue fell 7% on purpose.
$1.42B, down from $1.53B — driven by previously disclosed market exits and disciplined payor contracting. agilon walked away from unprofitable business.
2
Medical margin grew 16%.
$149M, vs. $128M YoY — per-member economics improving even as total members shrank from 605K to 536K.
3
Adjusted EBITDA more than doubled.
$54M in Q1 2026 vs. $21M a year earlier (+162%) — first quarter of clearly positive adjusted EBITDA in the post-cost-trend-surprise era.
4
Net income reached $49M.
Up from $12M — though much of the GAAP improvement reflects the same operational improvements that drove adjusted EBITDA, plus lower geography-entry costs.
5
Balance sheet is strong.
$303M cash and marketable securities against $32M of total debt — agilon doesn't have a liquidity problem, only an execution one.
6
Tim O'Rourke named CEO.
Bringing 25+ years of healthcare leadership. Executive Chairman Ron Williams (former Aetna CEO) continues as strategic overseer.
7
FY2026 guidance was raised across the board.
Revenue $5.68-5.81B (up from $5.41-5.58B); medical margin $350-400M (up from $300-350M); adjusted EBITDA $10-40M (up from -$15 to $15M).